Arbutus Biopharma Corporation
ABUS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $14.1M | $6.17M | +128% |
| Operating income | −$38.2M | −$76.3M | +50.0% |
| Net income | −$33.5M | −$69.9M | +52.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 10, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $300K | $500K | −40.0% |
| Operating income | −$10.5M | −$8.70M | −20.7% |
| Net income | $59.1M | −$7.70M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Arbutus's revenue in FY2025?
- $14.1M in FY2025 (Fiscal year ended Dec 31, 2025), +128% vs $6.17M a year earlier, per its 10-K filed Mar 2026.
- Was Arbutus profitable in FY2025?
- No: net income was −$33.5M and operating income −$38.2M in FY2025.
- What was Arbutus's revenue in Q3 2026?
- $300K (−40.0% vs a year earlier), per its Form 10-Q filed Nov 10, 2026.